Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

PURPOSE: To investigate whether anti–vascular endothelial growth factor therapy with bevacizumab prolongs progression-free survival (PFS) when added to first-line letrozole as treatment of hormone receptor–positive metastatic breast cancer (MBC). PATIENTS AND METHODS: Women with hormone receptor–pos...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Dickler, Maura N., Barry, William T., Cirrincione, Constance T., Ellis, Matthew J., Moynahan, Mary Ellen, Innocenti, Federico, Hurria, Arti, Rugo, Hope S., Lake, Diana E., Hahn, Olwen, Schneider, Bryan P., Tripathy, Debasish, Carey, Lisa A., Winer, Eric P., Hudis, Clifford A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2016
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5012690/
https://ncbi.nlm.nih.gov/pubmed/27138575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.66.1595
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi